Every Cure has received a five-year $60m investment to advance its artificial intelligence-based platform identifying generic and off-patent drugs that could be repurposed for various diseases.
The US-based nonprofit biotech prides itself on utilizing “AI to unleash the potential of every approved medicine to treat every disease it possibly can” by generating predictive efficacy
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?